Ebola virus (EBOV) is a highly pathogenic virus causing severe hemorrhagic fever with a
high case fatality rate of 50% - 90% in humans. Without an approved vaccine or treatments, Ebola outbreak
management has been limited to palliative care and barrier methods to prevent transmission.
These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in
West Africa. As with the increase of outbreaks, a significant effort has been made to develop promising
countermeasures for the prevention and treatment of Ebola virus infection. In this review, development
of therapeutics and potential inhibitors for Ebola virus infection will be discussed.